Ted Roh: Indonesia’s Plasma Fractionation Plant Wins Social Infrastructure Deal of the Year at the IJGlobal Awards 2025
Ted Roh, President at SK Plasma Core Indonesia, shared on LinkedIn:
”Indonesia’s Plasma Fractionation Plant Recognized as Social Infrastructure Deal of the Year, APAC at IJGlobal Awards 2025
Singapore, May 2026 – Indonesia’s first plasma fractionation facility, developed through a partnership between Indonesia Investment Authority (INA) and SK Plasma through their joint venture PT SKPlasma Core Indonesia, has been recognized as Social Infrastructure Deal of the Year, APAC at the IJGlobal Awards 2025.
The award acknowledges the development of essential healthcare infrastructure addressing Indonesia’s reliance on imported Plasma Derived Medicinal Products (PDMPs), and reflects the project’s ability to bring together the necessary expertise, capital, and partnerships to support long-term healthcare development in Indonesia.
Organized by IJGlobal, the awards are presented to notable greenfield and refinancing transactions across the energy and infrastructure sectors.
Winners are selected by an independent panel of industry professionals through a structured evaluation process, with submissions assessed against criteria such as innovation, impact, and execution, and ultimately determined through a consensus-based decision.
The plasma fractionation facility, currently under development in Karawang, West Java, represents a significant step toward strengthening Indonesia’s healthcare resilience.
Once operational, the facility is expected to enable domestic processing of blood plasma into life-saving therapies such as immunoglobulin and albumin, supporting more reliable and affordable access to essential medicines.
Since the initial investment announcement in December 2024, the project has progressed through key milestones, including the introduction of plasma-derived products sourced from Indonesian donor plasma, as well as the advancement of construction for the local facility, which is targeted to commence operations by 2027.
Financing for the project has also been strengthened through a syndicated loan of IDR 3.7 trillion, led by PT Allo Bank Indonesia Tbk, alongside PT Bank Mega Tbk, supporting the continued development and readiness of the facility.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 17:11Owen McCarty: Understanding Prekallikrein and Its Role in Inflammation and Thrombosis
-
Oct 18, 2026, 17:04Emna Gouider Belhadjali: Don’t Miss GPAS 2026 on Bleeding Disorders
-
Oct 18, 2026, 16:53Mehran Ghasemzadeh: Microparticle-Associated Mitochondrial DNA in Stored Platelet Products
-
Oct 18, 2026, 16:38Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?
-
Oct 18, 2026, 16:29Patrick Taylor: Oral vs Transdermal Estrogen and Cardiovascular Risk in Menopausal Women
-
Oct 18, 2026, 16:19Artangela Henry: A Meaningful Week at the SCDAA National Convention
-
Oct 18, 2026, 16:04Emília Araújo։ New Insights Into the Genetics of Hemophilia B Leyden
-
Oct 18, 2026, 15:43André Marcel Harris: Award-Winning Research on Texas Sickle Cell Data Collection
-
Oct 18, 2026, 15:21Eleonora Gambineri: First Results of the IEI-Haem Consortium at ESID 2026